Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01125176
Title Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications

chronic lymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Lenalidomide + Rituximab + Thalidomide

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.